Abstract Mortality after breast cancer diagnosis is known to vary by race/ethnicity even after adjustment for differences in tumor characteristics. As adjuvant hormonal therapy decreases risk of recurrence and increases overall survival among women with hormone receptor-positive tumors, treatment disparities may play a role. We explored racial/ethnic differences in initiation of adjuvant hormonal therapy, defined as two or more prescriptions for tamoxifen or aromatase inhibitor filled within the first year after diagnosis of hormone receptor-positive localized or regional-stage breast cancer. 63-0.98, respectively). Within an equal access, insured population, lower levels of initiation of adjuvant hormonal therapy were found for Hispanic and Chinese women. Findings need to be confirmed in other insured populations and the reasons for under-initiation among these groups need to be explored.
Introduction
Five-year age-adjusted breast cancer survival rates in the US are highest among Asian/Pacific Islanders (89.4%) This work was conducted while Jennifer Livaudais was a doctoral student at the University of Washington, School of Public Health, and a research fellow at the Fred Hutchinson Cancer Research Center, Seattle, WA.
followed by non-Hispanic White (87.5%), Hispanic (85.3%) and African American women (75.0%) [1] . Among Asian American subgroups, survival is highest among Japanese (91.5%) followed by Chinese (85.5%) and Filipina women (85.3%) [2] .
African American and Hispanic women remain at increased risk of breast cancer death compared to nonHispanic White women, even after adjustment for stage, hormone receptor status, socioeconomic status, surgical and radiation treatment (HR = 1.5 and HR = 1.1, respectively) [3] . Differences in the use of other types of breast cancer treatment not captured by population-based cancer registries, including adjuvant chemotherapy and adjuvant hormonal therapy, may contribute to remaining survival differences [3] [4] [5] .
Adjuvant hormonal therapy is associated with improved disease-free and overall survival among women with hormone receptor-positive breast cancer, irrespective of age, menopausal status, lymph node status or chemotherapy use [6] [7] [8] . A small number of studies to date have documented racial/ethnic differences in use of adjuvant hormonal therapy, indicating that compared with non-Hispanic White women, Chinese [9] , African American [4, 10, 11] and Hispanic women [10] are significantly less likely to use adjuvant hormonal therapy.
The optimal duration of use for adjuvant hormonal therapy is 5 years [12, 13] , and early discontinuation and non-adherence to adjuvant hormonal therapy have been associated with mortality [8] . Although few studies have reported on racial/ethnic differences in adherence to adjuvant hormonal breast cancer therapy, a variety of other factors have been associated with non-adherence, including patient perception of low risk for recurrence [14] , experience of adverse events from use [15] [16] [17] , older patient age [18] , low socioeconomic status regardless of health insurance status [19] , poor patient-provider communication [20] and psychological factors [16] . These factors may differ across racial/ethnic groups, leading to differences in adherence and contributing to racial/ethnic differences in breast cancer survival.
To build on findings from prior studies, we examined whether there were racial/ethnic differences in initiation of adjuvant hormonal therapy among a large, racially and ethnically diverse population of women enrolled in Kaiser Permanente Northern California (KPNC), diagnosed with hormone receptor-positive breast cancer between January 1, 1996 and June 30, 2007 . In light of persistent racial/ ethnic differences in breast cancer survival in the US after controlling for tumor characteristics and surgical and radiation treatment, we were interested in examining whether there were racial/ethnic differences in the initiation of adjuvant hormonal therapy within the KPNC population. Cancer registry and Census data were available for 20,421 women who were diagnosed with breast cancer between January 1, 1996 and June 30, 2007 and enrolled in KPNC during the year before diagnosis. The cancer registry records information on hormone receptor status, as obtained from pathology reports, and 15,730 women in the sample were diagnosed with hormone receptor-positive breast cancer; 3,786 women with hormone receptor-negative tumors (negative for both ER and PR) and 905 women with tumors of unknown hormone receptor status were excluded.
Methods

Study
Among women with hormone receptor-positive breast cancer, 15,320 were diagnosed with localized or regionalstage breast cancer, classified according to SEER summary staging; 15,035 of these women were identified in the KPNC cancer registry to be non-Hispanic White, Hispanic, African American, Chinese, Japanese, Filipino or South Asian (Asian Indian or Pakistani). All other racial/ethnic groups were excluded. Of the remaining sample, 13,863 women were between the ages of 20 and 79 years at the time of diagnosis, and our final sample included 13,753 of these women who remained enrolled in KPNC for at least 1 year after breast cancer diagnosis. Our sample differed from two prior studies on adjuvant hormonal therapy adherence in KPNC, whose sample selection criteria resulted in the inclusion of primarily stage I patients [8, 21] .
Data measures
Initiation of adjuvant hormonal breast cancer treatment
For each woman, prescriptions for tamoxifen, anastrazole, exemestane and letrozole within the first year after diagnosis were reviewed from KPNC outpatient pharmacy data. Women with at least two documented prescriptions filled for any of these medications within this time period were considered to have initiated adjuvant hormonal therapy. This definition is distinct from prior analyses of KPNC data [8, 21] that defined initiation as one or more prescriptions filled. In our analysis, women with no records for these medications documented in KPNC pharmacy data, women with only one filled prescription and women initiating their first two prescriptions later than 1 year after breast cancer diagnosis were considered to be non-initiators. This time restriction was applied because of (a) the lack of reliable information on recurrences from electronic data and (b) the low likelihood of recurrences within the first year after diagnosis (reported to be \5% overall in similarly staged patients) [22] . We wanted to avoid classifying women who began treatment later than 1 year after diagnosis as ''initiators,'' given the possibility that they initiated therapy to treat recurrent rather than primary breast cancer.
Race/ethnicity
Race/ethnicity information in KPNC is typically obtained on inpatient admission, or at the time of breast cancer diagnosis or admission for treatment. Race/ethnicity may be directly obtained from the patient or a relative or inferred by the attending health professional based on observation. Cancer registrars abstract this information and it is recorded in the patient's cancer registry record. Only women who were identified as non-Hispanic White, Hispanic, African American, Chinese, Japanese, Filipino or South Asian were included in the sample. Categories are provided as mutually exclusive.
Covariates
Covariates of interest as potential confounding characteristics included age at diagnosis, marital status and year of diagnosis. Geocoded information on area-level education, poverty and income pertaining to 2000 Census-block group of residence at time of diagnosis was also available, and an aggregate score for socioeconomic status (SES) was generated for each patient following the methods outlined by Yost et al. [23] . Component SES scores were categorized into quintiles based on the California statewide distribution.
ICD-9-CM diagnostic codes in KPNC inpatient and outpatient claims from patient visits beginning 1 year before breast cancer diagnosis were reviewed to identify those with a history of any of the comorbid conditions included in the Klabunde adaptation of the Charlson comorbidity index [24, 25] . Each condition was weighted accordingly, and each patient was assigned a summary score based on this index.
Tumor stage (localized or regional), size (\1 or C1 cm), grade (I-IV) and histology type (ductal [ICD-O code 8500], lobular/mixed ductal lobular [ICD-O codes 8520, 8522 and 8524], all other specified types) were available from KPNC cancer registry records. Surgical breast cancer treatment (lumpectomy or mastectomy) and receipt of radiation and chemotherapy were obtained from KPNC cancer registry records on ''first course of treatment.''
Statistical analysis
Distributions of key demographic and breast cancer tumor characteristics, prognostic factors and other covariates were examined across racial/ethnic groups, and comparing initiators to non-initiators. Descriptive statistics presented are based on non-missing values, and percentages of cases with missing data are provided in table footnotes. Chisquare tests were used to assess significant differences between groups with respect to categorical variables, and ttests were used to assess differences with respect to continuous variables (two-tailed significance level P \ 0.05).
Odds ratios [OR] and 95% confidence intervals [CI] were estimated for each racial/ethnic group using logistic regression with robust variance adjustment, comparing initiation of adjuvant hormonal therapy to non-Hispanic White women as the referent category. Covariates selected for inclusion in the logistic regression model were those associated in bivariate analysis with race/ethnicity, and with initiation among non-Hispanic White women. The final model included age at diagnosis, year of diagnosis, marital status, quintile of aggregate SES, Charlson comorbidity score, SEER stage, tumor histology, tumor grade and first course of treatment, including type of surgical and radiation treatment, and use of chemotherapy. Analyses were conducted using Stata/SE Version 11.0.
We examined whether the association between race/ ethnicity and initiation of adjuvant therapy varied according to (a) early versus late onset of breast cancer (\55 years of age vs. C55 years) and (b) area-level SES (quintiles 1-3 vs. quintiles [4] [5] . Interactions for each of these variables were explored using the Wald test (significance level P \ 0.05) but were not statistically significant.
Results
Patient characteristics
A total of 13,753 women in the KPNC system met eligibility criteria. Non-Hispanic White women made up the majority of the sample (76%), followed by Hispanic (8%), African American (6%), Filipino (4%), Chinese (4%), Japanese (2%) and South Asian women (\1%) (see Table 1 ). Mean age at diagnosis was 59 years (SD = 11). Non-Hispanic White and Japanese women were the oldest on average at time of diagnosis, whereas South Asian women were the youngest. African American women were the least likely to be married or living with a partner, and lived in areas of lowest SES. Japanese women lived in areas of highest SES. Comorbid conditions were most common among African American women and least common among South Asian women. Localized stage tumors were most common among Chinese, Japanese and non-Hispanic White women. Ductal tumors were most common among Chinese, Japanese and Filipino women. High-grade tumors (Cgrade II) were most common among African American and Filipina women. Use of chemotherapy treatment was least common among non-Hispanic White women and most common among South Asian women.
A total of 9,568 women (70%) were identified through KPNC pharmacy records as having filled at least two prescriptions for adjuvant hormonal therapy during the first year after diagnosis; 80% of women had filled at least one prescription (data not shown). Compared with non-initiators, initiators were older on average, more likely to be married or living with a partner, have regional-stage disease, larger tumors, lobular histology and higher-grade tumors. They also were more likely to have undergone mastectomy, or lumpectomy with radiation, and less likely to have used chemotherapy. Characteristics of this sample are further described in Table 1 .
Multivariable logistic regression
In multivariable-adjusted logistic regression analysis, Chinese and Hispanic women were less likely than nonHispanic White women to initiate adjuvant hormonal therapy (OR = 0.82, CI = 0.71-0.96 and OR = 0.78; CI = 0.63-0.98, respectively) (see Table 2 ). Initiation rates were similar comparing non-Hispanic White to African American, Filipino and South Asian women. Although findings did not reach statistical significance, we observed a trend toward greater likelihood of initiation among Japanese women.
Age at diagnosis was positively associated with initiation of therapy, as was year of diagnosis, and being married or living with a partner (see Table 2 ). Women with one or more comorbidities were less likely to initiate therapy, as were women with tumors of ''other specified histology'' compared with those with ductal tumors. Women with regional tumors were more likely to initiate than women with localized tumors, as were women with lobular compared with ductal tumors, and those with grade II compared with grade I tumors. Women who underwent lumpectomy with no radiation compared with mastectomy were less likely to initiate.
Discussion
A substantial majority of women diagnosed with hormone receptor-positive breast cancer within the integrated health system of KPNC initiated adjuvant hormonal therapy in the first year after diagnosis. On average, 70% of women diagnosed between January 1, 1996 and June 30, 2007 initiated therapy. Compared with non-Hispanic White women, initiation of adjuvant hormonal therapy was less common among Chinese and Hispanic women. There was a suggestion of more frequent initiation among Japanese women. However, there were relatively few Japanese women in the sample, limiting our ability to detect a more definitive association.
The percentage of women initiating adjuvant hormonal therapy increased over time, from 67% between 1996 and 2001 to 72% between 2002 and 2007. The increase was similar for each racial/ethnic group, and observed racial/ ethnic differences in initiation were similar across diagnosis years. Consistent with prior studies, we found that tumor characteristics (stage, histology and grade) were independently associated with initiation of adjuvant hormonal therapy [26] as was the presence of comorbid conditions [26] and prior surgical and radiation treatment. Racial/ethnic differences in initiation persisted in the KPNC population despite adjustment for these factors in multivariable analysis.
Our results for Hispanic women are consistent with findings from one of the only other studies to include Hispanic women, documenting a significantly lower likelihood of adjuvant hormonal therapy use among Hispanic versus non-Hispanic White women (OR = 0.95) [10] . Our findings are also similar to the one other study that considered initiation in Asian populations [9] . In that population-based study of women identified from the Greater Bay Area Cancer Registry diagnosed with localized breast cancer in 1994 at C50 years of age, Chinese women were more likely than non-Hispanic White women to experience non-use of adjuvant hormonal therapy for estrogen receptor-positive tumors (OR non-use = 2.3) [9] . Four prior studies examined the use of adjuvant hormonal therapy in African American women [4, 10, 11, 26] . Two of these studies [4, 11] reported that non-Hispanic White women were more likely to use adjuvant hormonal therapy than African American women (OR = 4.59 [4] and OR = 2.09 [11] ), and the third study [10] reported a lower likelihood of adjuvant hormonal therapy use among African American compared with non-Hispanic White women (OR = 0.91). These findings are in contrast to our results, as we observed no differences in initiation between African American and non-Hispanic White women.
The fourth study also reported a greater likelihood of adjuvant therapy non-use among African American and Hispanic women, compared with non-Hispanic White women (OR non-use = 2.0) [26] . However, the principal outcome combined use of hormonal and chemotherapy, and African American and Hispanic women were grouped together [26] , precluding our ability to compare findings for African American or Hispanic women alone.
The difference in results between our study and these prior studies that included African American women [4, 10, 11, 26] may reflect that our population was contained within the KPNC health care system. All women in our study had health insurance, and healthcare was delivered through an integrated system, minimizing differences in access to care that may exist in the other studies. This may help to explain the lack of difference in initiation we observed between African American and non-Hispanic White women. Quintile of aggregate SES was not associated with initiation in KPNC, supporting this notion. As all KPNC members were insured, SES did not have the same impact on treatment as it might have had in a population of women with varying levels of access to care. Women in KPNC also tended to live in areas of higher average SES compared with the California population statewide, as evidenced by the over-distribution of KPNC members in the highest quintiles of SES.
Treatment recommendations made by physicians are also influential [27] [28] [29] . Information was not readily available in the KPNC cancer registry or pharmacy records on whether women's physicians recommended adjuvant hormonal therapies, so we were unable to determine whether treatment was influenced primarily by physician recommendation or by other factors. Based on breast cancer tumor profile alone, adjuvant hormonal therapy should have been recommended by physicians for all women included in our analysis, with potential exceptions for those with a history of blood clots, stroke, uterine cancer or osteoporosis [30, 31] . Information on these and other comorbid conditions was available from KPNC inpatient and outpatient records, and we were able to account for these conditions in our analysis with adjustment for the Charlson comorbidity score.
Other factors may contribute to observed differences in initiation across racial/ethnic groups. Hispanic breast cancer survivors, particularly those who are Spanish speakers, have expressed difficulty obtaining and using interpreters in the health care system [32] , which may interfere with [32] . Knowledge about the benefit of therapy has a significant impact on use [17, 33] , and language difficulties and low health literacy among less acculturated Hispanic and Chinese women may inhibit full comprehension of available treatment options and their risks and benefits. Future research should consider these factors. The lower likelihood of adjuvant hormonal therapy initiation among Chinese women relative to non-Hispanic White women in KPNC might at first appear to contradict the lower risk of breast cancer mortality documented among Asian American versus non-Hispanic White women in the US [3] . However, a prior analysis of KPNC data documented lower rates of discontinuation of adjuvant hormonal therapy among Asian American women, compared with non-Hispanic White women [21] . Although our analysis found that Chinese women in KPNC are less likely to initiate adjuvant hormonal therapy, those who initiate may adhere to treatment for longer periods of time, positively affecting survival.
The large size and ethnic diversity of our study population are particular strengths, enabling us to examine initiation of adjuvant hormonal therapy among individual Asian subgroups. There was heterogeneity in the KPNC population with respect to the direction and magnitude of the odds ratios associated with use of adjuvant hormonal therapy across different Asian subgroups. Studies combining women of different Asian ethnicities into one group may obscure important associations for individual subgroups. We were not able to look at individual subgroups of Hispanic women in our analysis based on unreliable information on country of origin, but differences in initiation across Hispanic subgroups will be important to examine in future studies.
An additional strength was the ascertainment of adjuvant hormonal therapy initiation from KPNC pharmacy records. Medical records are considered the gold standard for collecting adjuvant breast cancer treatment information [34, 35] as cancer registry records tend to underestimate use [36] . SEER records typically only include treatment received or planned during the first 4-6 months after diagnosis, and many women may not begin these therapies until after this period.
Furthermore, as KPNC members received their prescriptions almost exclusively from KPNC pharmacies (90%), we expect that our ascertainment of filled prescriptions was virtually complete. Defining ''initiation'' as two or more filled prescriptions within the first year after diagnosis could have led to some misclassification of women who filled the first prescription and actually did use the medication, but never refilled the prescription. Our strict definition of initiation may also explain why the percentages of initiation are lower than those reported by other studies [11, 26] . However, we believe that categorization of initiation as two or more filled prescriptions provides the best estimate of actual patient use.
We did not explore differences across racial/ethnic groups in adherence to adjuvant hormonal therapy, and as outlined in our introduction, early discontinuation and nonadherence to adjuvant hormonal therapy have been associated with mortality in the KPNC population [8] . An additional limitation is the potential for misclassification of race/ethnicity as it was obtained from the cancer registry. Previous research indicates that the total numbers of African American, Hispanic and Asian/Pacific Islander women are underestimated by SEER [37, 38] . However, any misclassification of race/ethnicity was likely non-differential between initiators and non-initiators of adjuvant hormonal therapy, and under this circumstance, effect estimates for each racial/ethnic group would be biased toward the null.
Conclusions
Within KPNC, 70% of women aged 20-79 years diagnosed with hormone receptor-positive breast cancer between January 1, 1996 and June 30, 2007 initiated adjuvant hormonal therapy within the first year after diagnosis. Rates of initiation of adjuvant hormonal therapy increased over time, but the associations between race/ethnicity and initiation were similar across diagnosis years. Chinese and Hispanic women were less likely to initiate therapy than non-Hispanic White women. Substantial differences in access to care are not likely to explain these results as all women in the KPNC sample were insured. Findings need to be confirmed in other populations of insured patients. If confirmed, alternative reasons for under-initiation among Chinese and Hispanic women need to be explored, and targeted interventions for those at highest risk for noninitiation will be warranted. Future examination of differences across racial/ethnic groups with respect to physicianpatient communication, patient understanding of and preferences for treatment, language barriers and cultural factors will be informative.
